¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦ 43 Â÷ KSTH Ãß°èÇмú´ëȸ : 2023-10-06

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦ 43 Â÷ KSTH Ãß°èÇмú´ëȸ : 2023-10-06
±³À°ÀÏÀÚ : 2023-10-06
±³À°Àå¼Ò : ÀÎÅͺҰíÈ£ÅÚ ´ë±¸ º»°ü 1F Áñ°Å¿îȦ, ÇູÇÑȦ

±³À°ÁÖÁ¦ : Á¦ 43 Â÷ KSTH Ãß°èÇмú´ëȸ

ÁÖÃÖ±â°ü : Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ
´ã´çÀÚ : ±èÁø¾Æ
¿¬¶ôó : 02-790-2426  

À̸ÞÀÏ : ksth@thrombo.or.kr

±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, À̺ñÀÎÈÄ°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, ÀÀ±ÞÀÇÇаú, ÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, »ý¸®ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ÀÇ·á»çȸÇÐ, ÀÇ·áÀ±¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À°, ÀÇ·áÁ¤Ã¥, ÀÇ·á¹ý, ÀÇ·á°æ¿µ, ±âŸ

Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 14 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 40,000¿ø  

ºñ°í ±âŸ 10,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 10¿ù 06ÀÏ È¦A(Áñ°Å¿îȦ) 08:50~09:00 °³È¸»ç ()

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 09:00~09:25 Updates in the management of acute pulmonary embolism ȲÇå±Ô(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 09:25~09:50 2022 ITAC guidelines for the treatment of VTE in patients with cancer ÀÌÁöÇö(µ¿¾ÆÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 09:50~10:15 Optimal strategy for thromboprophylaxis in Patients with COVID-19 ³ª»óÈÆ(¼­¿ïÀÇ´ë)

Åä·Ð 10¿ù 06ÀÏ È¦A 10:15~10:30 Discussion ¹æ¼ö¹Ì, ±è¾ç±â(¼­¿ïÀÇ´ë, ¼øõÇâÀÇ´ë)

ÈÞ½Ä 10¿ù 06ÀÏ 10:30~10:45 coffee break ()

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 10:45~11:10 Contemporary biomarker in VTE: diagnosis and prognosis ¾È¾Æ¸®(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 11:10~11:35 Genetics of VTE: Cloncal hematopoiesis ±è°æÇÏ(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 11:35~12:00 Microbiome in venous thromboembolism À±¼®À±(¼øõÇâÀÇ´ë)

Åä·Ð 10¿ù 06ÀÏ È¦A 12:00~12:15 Discussion À强¼ö, ³ª»óÈÆ(¿ï»êÀÇ´ë, ¼­¿ïÀÇ´ë)

½Ä»ç 10¿ù 06ÀÏ 12:15~13:30 ÆòÀÇ¿øȸ/Lunch ()

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 13:30~13:55 Proximal complement inhibitor in PNH Á¤Çظ²(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 13:55~14:20 Considerations regarding long-term treatment with eculizumab in atypical HUS : Discontinuation and special situations (pregnancy, infection, etc.) À¯Àº»ó(°í·ÁÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 14:20~14:45 Plasma exchange in thrombotic microangiopathies other than TTP ±è»ó¾Æ(¼­¿ïÀÇ´ë)

Åä·Ð 10¿ù 06ÀÏ È¦A 14:45~15:00 discussion ±èÁø¼®, ÀÓÈ£¿µ(¿¬¼¼ÀÇ´ë, ÀüºÏÀÇ´ë)

ÈÞ½Ä 10¿ù 06ÀÏ 15:00~15:20 coffee break ()

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 15:20~15:35 (±¸¿¬¹ßÇ¥)Comparison of Optical Coherence Tomographic -Polymer-free Everolimus- and Sirolimus-eluting Stents in a Porcine Model ±è¹Î°æ(¿µ³²ÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 15:35~15:50 (±¸¿¬¹ßÇ¥)A clinical decision support tool for differential Diagnosis of TMA ÃÖ¿øÀÏ(¸íÁöº´¿ø)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 15:50~16:05 (±¸¿¬¹ßÇ¥)Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention À̽ÂÇå(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 16:05~16:20 (±¸¿¬¹ßÇ¥)HDAC5 Inhibition Reduces ±âÇØÁø(Àü³²ÀÇ´ë)

ÈÞ½Ä 10¿ù 06ÀÏ 16:20~16:30 Poster viewing ()

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 16:30~16:55 Recent basic researches of hemophilia ¹Úö¿ë(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 16:55~17:20 Management of bleeding in hemophilia during emicizumab treatment ¹Ú¿µ½Ç(°æÈñÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦A 17:20~17:45 Recombinant porcine factor VIII for hemostatic treatment in acquired hemophilia A Çö½Å¿µ(¿¬¼¼ÀÇ´ë)

Åä·Ð 10¿ù 06ÀÏ È¦A 17:45~18:00 discussion À¯Ã¶¿ì, À¯Ã¶ÁÖ(À»ÁöÀÇ´ë, ¿¬¼¼ÀÇ´ë)

±âŸ 10¿ù 06ÀÏ È¦A 18:00~18:10 Æóȸ½Ä ()

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B(ÇູÇÑȦ) 09:00~09:25 Pathogenesis and role of platelet autoantibodies in the diagnosis of patients with immune thrombocytopenia ±èÁÖ¿ø(¿¬¼¼¿øÁÖÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 09:25~09:50 Prediction for the diagnosis and clinical course of immune thrombocytopenia ±èÁöÀ±(°æºÏÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 09:50~10:15 Practical aspects of TPO-RA use in immune thrombocytopenia ½Åµ¿¿±(¼­¿ïÀÇ´ë)

Åä·Ð 10¿ù 06ÀÏ È¦B 10:15~10:30 Discussion À±¼º¼ö, ±è¼ºÇö(¼­¿ïÀÇ´ë, µ¿¾ÆÀÇ´ë)

ÈÞ½Ä 10¿ù 06ÀÏ 10:30~10:45 coffee break ()

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 10:45~11:10 Platelet function test ¼ÛÀç¿ì(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 11:10~11:35 Diagnosis of inherited thrombocytopenias and platelet function disorders ±èº¸Çö(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 11:35~12:00 Acquired disorders of platelet function ¹Ú»óÇõ(¿ï»êÀÇ´ë)

Åä·Ð 10¿ù 06ÀÏ È¦B 12:00~12:15 Discussion ¿Àµµ¿¬, ¹Ú³ëÁø(õ¾ÈÀÇ·á¿ø, ¼øõÇâÀÇ´ë)

½Ä»ç 10¿ù 06ÀÏ 12:15~13:30 Lunch ()

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 13:30~13:55 Cardiovascular complications in chronic kidney disease À§Áø(°¡ÃµÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 13:55~14:20 Does transient AF require anticoagulation therapy ? ÇÑ»óÁø(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 14:20~14:45 Catheter-related arterial thrombosis & bleeding ¹ÎÇʱâ(¿¬¼¼ÀÇ´ë)

Åä·Ð 10¿ù 06ÀÏ È¦B 14:45~15:00 discussion ¾È¿µ±Ù, ±è¿ø(Àü³²ÀÇ´ë, °æÈñÀÇ´ë)

ÈÞ½Ä 10¿ù 06ÀÏ 15:00~15:20 coffee break ()

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 15:20~15:35 (±¸¿¬¹ßÇ¥2)Real-world Features and Clinical Significance of Late Presentation Among Patients with ST Elevation Myocardial Infarction Á¶°æÈÆ(Àü³²ÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 15:35~15:50 (±¸¿¬¹ßÇ¥2)Mitochondrial MsrB2 ±è¼öÁ¾(ÃæºÏ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 15:50~16:05 (±¸¿¬¹ßÇ¥2)Korean Adult Atypical Hemolytic Uremic Syndrome À±Àç¿ø(Áß¾Óº¸Èƺ´¿ø)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 16:05~16:20 (±¸¿¬¹ßÇ¥2)ST-elevation and non-ST-elevation myocardial infarction:From the KAMIR-NIH Registry À̽ÂÈñ(±¹¸³º¸°Ç¿¬±¸¿ø)

ÈÞ½Ä 10¿ù 06ÀÏ 16:20~16:30 Poster viewing ()

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 16:30~16:50 Hypertension, microvascular thrombosis, and organ damage ¼­Àçºó(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 16:50~17:10 Thrombosis in cardiometabolic syndrome ±è¿øÁø(Â÷ÀÇ´ë)

±³À°½Ã°£ 10¿ù 06ÀÏ È¦B 17:10~17:30 Effect of statins on vascular thromboembolism ±èÇöÁø(ÇѾçÀÇ´ë)

Åä·Ð 10¿ù 06ÀÏ È¦B 17:30~18:00 panel discussion À§Áø, ÀÓÈ£¿µ, ±è¼ºÀº(°¡ÃµÀÇ´ë, ÀüºÏÀÇ´ë, ÇѸ²ÀÇ´ë)

±âŸ 10¿ù 06ÀÏ È¦B 18:00~18:10 Æóȸ½Ä ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦ 43 Â÷ KSTH Ãß°èÇмú´ëȸ : 2023-10-06""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼­¿ï´ëÇб³º´¿ø 2023 Seoul Liver Symposium : 2023-10-06
´ÙÀ½±Û ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ IGET(Image Guided Endovascular Therapy) Live Symposium 2023 3ÀÏÂ÷ : 2023-10-06
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
285 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø 1) ÇǺΠÇ÷°ü Áúȯ 2) »ö¼Ò ÀÌ»óÁõ : 2018-09-27 0 775 2018-07-28
284 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¾È°ú ±Ý¿ä¼¼¹Ì³ª(Æó¼â°¢ ³ì³»Àå) : 2018-09-21 0 1,427 2018-07-28
283 ´ë±¸ ´ëÇѽÅÀåÇÐȸ ´ë±¸-°æºÏÁöȸ ¿¬¼ö °­Á : 2018-09-20 0 668 2018-07-28
282 ¼­¿ï °Ç±¹´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2018-09-20 0 393 2018-07-28
281 ¼­¿ï [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] 4Â÷ »ê¾÷Çõ¸í°ú ÀÇ·áÀÇ ¹Ì·¡ : 2018-09-20 0 644 2018-07-28
280 ¼­¿ï ¼­¿ïƯº°½ÃÀÇ»çȸ Á¦5Â÷ ȸ¿ø¿¬¼ö±³À°(Áø´Ü¸í¿¡ µû¸¥ ÀûÀýÇÑ Ã³¹æ) : 2018-09-20 0 850 2018-07-28
279 °­¿ø ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø Á¦ 130ȸ ¼ÒÈ­±â¼¾ÅÍ ¿¬¼ö±³À° : 2018-09-19 0 743 2018-07-28
278 ¼­¿ï Çѱ¹ºÐÀÚ¼¼Æ÷»ý¹°ÇÐȸ Á¤±âÇмú´ëȸ : 2018-09-19 0 504 2018-07-28
277 ¼­¿ï ¼ÛÆı¸(4Â÷) °³¿øÀÇ ¿¬¼ö±³À°(¿äÅëȯÀÚ, °ñ´Ù°øÁõ) : 2018-09-18 0 510 2018-07-28
276 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø ¾È°úÁö¿ªÀÇ»ç Áý´ãȸ : 2018-09-18 0 536 2018-07-28
275 °æ±â Â÷ÀÇ°úÇдëÇб³ºÐ´çÂ÷º´¿ø ³ì³»Àå : 2018-09-18 0 667 2018-07-28
274 ´ë±¸ ´ëÇѽŰæ°úÇÐȸ ´ë°æÁöȸ - ´ë°æ½Å°æ°úÀÇ»çȸ °øµ¿ ½ÉÆ÷Áö¿ò : 2018-09-18 0 1,514 2018-07-28
273 ¼­¿ï Çѱ¹ºÐÀÚ¼¼Æ÷»ý¹°ÇÐȸ Á¤±âÇмú´ëȸ : 2018-09-18 0 623 2018-07-28
272 ¼­¿ï Çѱ¹ºÐÀÚ¼¼Æ÷»ý¹°ÇÐȸ Á¤±âÇмú´ëȸ : 2018-09-17 0 436 2018-07-28
271 °æ±â Á¦ 1ȸ ¾ÆÁִ뺴¿ø ½ÅÀå³»°ú ¿¬¼ö°­Á : 2018-09-16 0 2,117 2018-07-28
1371 | 1372 | 1373 | 1374 | 1375 | 1376 | 1377 | 1378 | 1379 | 1380
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷